W.P. Arnold
Radboud University Nijmegen
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by W.P. Arnold.
British Journal of Dermatology | 2014
J.M.P.A. van den Reek; J. Zweegers; Wietske Kievit; M.E. Otero; P.P.M. van Lümig; R.J.B. Driessen; P.M. Ossenkoppele; M.D. Njoo; J.M. Mommers; M.I.A. Koetsier; W.P. Arnold; B.A.M. Sybrandy-Fleuren; A.L.A. Kuijpers; M.P.M. Andriessen; P.C.M. van de Kerkhof; M.M.B. Seyger; E.M.G.J. de Jong
Drug survival is a marker for treatment success. To date, no analyses relating dermatological quality‐of‐life measures to drug survival have been published.
British Journal of Dermatology | 2017
J. Zweegers; J.M.M. Groenewoud; J.M.P.A. van den Reek; M.E. Otero; P.C.M. van de Kerkhof; R.J.B. Driessen; P.P.M. van Lümig; M.D. Njoo; P.M. Ossenkoppele; J.M. Mommers; M.I.A. Koetsier; W.P. Arnold; M.P.M. Andriessen; A.L.A. Kuijpers; M.A.M. Berends; Wietske Kievit; E.M.G.J. de Jong
The efficacy of etanercept and ustekinumab in psoriasis has been compared in one randomized controlled trial. Comparison of the long‐term effectiveness of biologics in daily‐practice psoriasis treatment is currently lacking.
British Journal of Dermatology | 2016
J. Zweegers; J.M.P.A. van den Reek; P.C.M. van de Kerkhof; M.E. Otero; A.L.A. Kuijpers; M.I.A. Koetsier; W.P. Arnold; M.A.M. Berends; L. Weppner-Parren; P.M. Ossenkoppele; M.D. Njoo; J.M. Mommers; P.P.M. van Lümig; R.J.B. Driessen; Wietske Kievit; E.M.G.J. de Jong
Predictors for successful treatment are important for personalized medicine. Predictors for drug survival of biologics in psoriasis have been assessed, but not split for different biologics or for the reason of discontinuation.
British Journal of Dermatology | 2014
J. Zweegers; J.M.P.A. van den Reek; P.C.M. van de Kerkhof; M.E. Otero; P.M. Ossenkoppele; M.D. Njoo; J.M. Mommers; M.I.A. Koetsier; W.P. Arnold; B.A.M. Sybrandy-Fleuren; A.L.A. Kuijpers; M.P.M. Andriessen; Wietske Kievit; E.M.G.J. de Jong
Treatment goals have been developed to optimize daily clinical practice psoriasis care, but have not yet been studied in real life.
British Journal of Dermatology | 2014
J.M.P.A. van den Reek; P.P.M. van Lümig; M.E. Kooijmans; J. Zweegers; P.C.M. van de Kerkhof; P.M. Ossenkoppele; Njoo; J.M. Mommers; M.I.A. Koetsier; W.P. Arnold; B.A.M. Sybrandy-Fleuren; A.L.A. Kuijpers; M.P.M. Andriessen; M.M.B. Seyger; Wietske Kievit; E.M.G.J. de Jong
Although the effectiveness of biologics for psoriasis has been measured extensively with objective outcome measures, studies based on subjective, patient‐reported outcome measures remain scarce.
British Journal of Dermatology | 2017
J. Zweegers; B. Roosenboom; P.C.M. van de Kerkhof; J.M.P.A. van den Reek; M.E. Otero; S. Atalay; A.L.A. Kuijpers; M.I.A. Koetsier; W.P. Arnold; Berends; L. Weppner-Parren; M. Bijen; Njoo; J.M. Mommers; P.P.M. van Lümig; R.J.B. Driessen; Wietske Kievit; E.M.G.J. de Jong
It is important to assess which patients with psoriasis are more likely to achieve high clinical responses on biologics.
Acta Dermato-venereologica | 1995
P.C.M. van de Kerkhof; S. de Mare; W.P. Arnold; P.E.J. van Erp
Journal of The American Academy of Dermatology | 1994
W.P. Arnold; P.C.M. van de Kerkhof
British Journal of Dermatology | 2001
W.P. Arnold; P. Van Andel; D. de Hoop; L. De Jong‐Tieben; M. Visser‐van Andel
Journal of The European Academy of Dermatology and Venereology | 1996
L. Witkamp; M.M.H.M. Meinardi; P.M.M. Bossuyt; P.C.M. van de Kerkhof; W.P. Arnold; D. de Hoop; F.H.J. Rampen; D.J. Tazelaar; G.R.R. Kuiters; B. Hamminga; R.E. Boelen; W.J.M. Habets; N.Verburgh-Van de Zwan; Jan D. Bos
Collaboration
Dive into the W.P. Arnold's collaboration.
